Foghorn therapeutics provides second quarter 2023 financial and corporate update

— initiating fhd-286 combination study in aml in the third quarter of 2023 — selective brm, arid1b, ep300, and cbp, targeting key regulators of gene expression, continue to advance toward ind — cash, cash equivalents, and marketable securities of $284.3 million, as of june 30, 2023, provides cash runway into the second half of 2025 cambridge, mass., aug. 04, 2023 (globe newswire) -- foghorn® therapeutics inc. (nasdaq: fhtx), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today provided a financial and corporate update in conjunction with the company's 10-q filing for the quarter ended june 30, 2023.
FHTX Ratings Summary
FHTX Quant Ranking